Introducing Our New Series
04
Advancing Medical Therapy & Innovation
W2G
-
1 in 4 will suffer from Mental Illness
​
-
1 in 5 will suffer from Depression
​
-
1 in 5 will suffer from Addiction
​
​
It’s Time To Change The Way We Look At Medicine…
Medical Thinking Redesigned
Research of Cannabis and Psilocybe and their efficacy on treating unmet mental health conditions such as PTSD, addiction dependency and anxiety.
Organic Production
Cannabis + Psilocybin
Psilocybin Highlights
-
Psilocybin Dealer Application Submitted Jan 2021
Cannabis Highlights
-
Cannabis License received Nov 2020
​
-
Cannabis Operations commence JAN 2021
-
Over 35 New Genetic Cannabis Strains
-
Cannabis Sales Begin April 2021
To Improve Health & Wellness by Growing, Standardizing & Supplying Medical Innovation
​
Way2Grow Biopharma (W2G) is a Health Canada licensed facility with a focus on a biomedical approach to wellbeing.
W2G is happy to announce the addition of psilocybin to our research applications (Section 56 Exemption) and our production line (Dealer License).
​
We believe wellness starts with a standardized organic growth plan.
Our goal is to refine, stabilize, and purify organic methodology to customize growth plans for a variety of psilocybin species, to produce standardized production and extraction methods necessary to reach consistent quality products.
02
Tissue Culture Lab
Cannabis + Psilocybin
Micropropagation is cutting edge technology that creates disease-free plants and increases plant yield.
​​
Our W2G uses top-of-the-line tissue culture breeding equipment.
​
Micropropagation has proven invaluable for gaining information about the differentiation of cells and about factors that control plant growth.
​
Our micropropagation lab allows us to rapidly clone cannabis plants with desirable traits and elite genetics while reducing disease, pests, and pathogens.
Micropropagation & Genetic Innovation
Psilocybin Highlights
-
Psilocybin Tissue Culture anticipated spring/summer 2021
Cannabis Highlights
-
Cannabis License received Nov/2020
-
Cannabis Tissue culture Lab operational Feb 2021
-
Pre-Orders start Feb 2021
-
Genetic Leasing & Sales Begin April/May 2021
03
Cannabis + Psilocybin Extraction
Facility I - Cannabis Extraction - License received Nov. 20, 2020
​
- ​On-site cannabis CBD/THC/TERPENE extraction using Ice Water Extraction & Ethanol Distillation
​​
- CBD/THC Sales April 2020
​​
Facility II - Psilocybin Extraction - License Pending Est. Spring/Summer 2021
​
- Focus on the extraction of Psilocybin compounds and on the identification and research of new compounds.
04
Cannabis + Psilocybin Research Lab
We believe wellness starts with a standardized organic growth.
W2G Biopharma begins with a focus on the unique growth plans through examination of genetics, environmental controls, monitoring, automation, and drying processes of a variety psilocybin mushroom species.

By standardizing growth plans and extraction techniques, Way2Grow Biopharma aims to create more consistent standards used in the production and extraction of psilocybin mushrooms. 

Through use of tissue culture and molecular biology, W2G is advancing psilocybin knowledge by developing a library of sequenced psilocybin spores.
Cannabis + Psilocybin Research Lab
HIGHLIGHTS
-
Psilocybin Application Submitted January 2020
-
Section 56 research exemption Draft Jan 2020
-
Research LABORATORY Summer 2021
-
Psilocybin Extraction License (Pending) Est.Spring/Summer 2021
*W2G Proprietary Blends Pending Health Canada DIN/NPN Approvals (not for sale)
Medical Sales + Global Distribution
05
-
Medical Sales License & EU-GMP Facilities allow for import/export product to/from other medically licensed facilities internationally.
​​
-
W2G Biopharma has a specialized team to draw up the import and export license paperwork to ensure we meet compliance and regulatory framework to import and export our W2G organic products.
​​
-
W2G is developing strong strategic global partnerships to promote safe and responsible production and distribution of cannabis products.